101P Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial.

Saved in:
Bibliographic Details
Title: 101P Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial.
Authors: Llombart Cussac, A.1, Prat, A.2, Pérez-García, J.M.3, Mateos, J.4, Pascual, T.2, Escrivà-De-Romani, S.5, Stradella, A.6, Ruiz-Borrego, M.7, Bermejo De Las Heras, B.8, Keyaerts, M.9, Sampayo-Cordero, M.10, Malfettone, A.10, Cortés, R.11, Galván, P.12, Cortés, J.3, Gebhart, G.9
Source: Annals of Oncology. 2020 Supplement 2, Vol. 31, pS50-S50. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2020.03.040